Poster exhibition
Antiviral therapy and resistance

Programme

• • Poster
  • P 019

  Cyclosporin A inhibits VSV infection by RIG-I mediated induction of CMPK2

  • Lars Meier (Marburg / DE)

   Antiviral therapy and resistance, Innate immunity
• • Poster
  • P 020

  Novel antivirals targeting the human cytomegalovirus alkaline nuclease UL98

  • Tianyu Zhang (Hamburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 021

  IFNα subtype-specific susceptibility of HBV in the course of chronic infection

  • PD Dr. Kathrin Sutter (Essen / DE)

   Antiviral therapy and resistance, Host cell factors and modulation
• • Poster
  • P 022

  Preclinical development of optimized DHODH inhibitors as broad-spectrum antivirals for the treatment of respiratory virus infections

  • Dr. Alexandra Herrmann (Gräfelfing / DE)

   Antiviral therapy and resistance, Host cell factors and modulation
• • Poster
  • P 024

  Validation of the cytomegalovirus nuclear egress complex as an antiviral target – assessment of covalently binding warhead compounds

  • Julia Tillmanns (Erlangen / DE)
  • Prof. Dr. Manfred Marschall (Erlangen / DE)

   Antiviral therapy and resistance, Structure, assembly, egress
• • Poster
  • P 025

  Automated high-throughput image-based screen discovers members of the Akt serine/threonine kinase family as potential targets for treatment of HEV virus infection

  • Mara Klöhn (Bochum / DE)

   Antiviral therapy and resistance, Host cell factors and modulation
• • Poster
  • P 026

  Identification of a selective glucocorticoid receptor modulator as HIV-1 latency-reversing agent

  • Dr. Sharmeen Fayyaz (Tuebingen / DE)

   Antiviral therapy and resistance, Viral pathogenesis and persistence
• • Poster
  • P 027

  Development of a liposomal formulation pipeline for inhalation application against SARS-CoV-2

  • Philipp Reus (Frankfurt / DE)

   Antiviral therapy and resistance, SARS-CoV-2
• • Poster
  • P 029

  Broad-spectrum antiviral diazadispiroalkane core molecules block attachment and cell-to-cell spread of Herpesviruses

  • Marie Knoblauch (Berlin / DE)
  • Prof. Dr. Elke Bogner (Berlin / DE)

   Antiviral therapy and resistance, Virus receptors and entry
• • Poster
  • P 030

  Metabolic modeling elucidates phenformin and atpenin A5 as broad-spectrum antiviral drugs

  • Dr. Raphael Jami (Tuebingen / DE)

   Antiviral therapy and resistance, SARS-CoV-2
• • Poster
  • P 031

  Regulation of SAMHD1 upon HCMV infection and potential of CDK4/6 inhibitors to suppress HCMV replication in macrophages

  • Georgios Vavouras Syrigos (Tuebingen / DE)

   Antiviral therapy and resistance, Host cell factors and modulation
• • Poster
  • P 032

  Resistance barrier, biological stability and binding properties of platelet-derived-growth-factor receptor alpha derivatives developed for inhibition of human cytomegalovirus

  • Prof. Dr. Christian Sinzger (Ulm / DE)

   Antiviral therapy and resistance, Virus receptors and entry
• • Poster
  • P 033

  A novel approach to bridge the gap from virology research to new antivirals

  • Dr. Andreas Kühbacher (Wuppertal / DE)

   Antiviral therapy and resistance
• • Poster
  • P 034

  Analysis of mutational history of multidrug-resistant genotypes with a mutagenetic tree model

  • Martin Pirkl (Cologne / DE)

   Antiviral therapy and resistance
• • Poster
  • P 035

  Effects of SARS-CoV-2 infection on GSK3 phosphorylation and the use of specific GSK3 inhibitors as antivirals

  • Dr. Natalia Ruetalo Buschinger (Tuebingen / DE)

   Antiviral therapy and resistance, SARS-CoV-2
• • Poster
  • P 036

  Insights into the antiviral activity of Hypericum perforatum extract and its ingredient hypericin

  • Fakry F. Mohamed (Muenster / DE)

   Antiviral therapy and resistance, SARS-CoV-2
• • Poster
  • P 037

  Human endogenous peptides derived from hemoglobin alpha reduce pro-viral autophagy

  • Dennis Freisem (Ulm / DE)

   Antiviral therapy and resistance, Innate immunity
• • Poster
  • P 038

  ATO (Arsenic Trioxide) impedes efficient HBV infection by interferance with PML-NBs

  • Dr. Samuel Hofmann (Hannover / DE)

   Antiviral therapy and resistance, Host cell factors and modulation
• • Poster
  • P 039

  Trans-delivery of defective interfering RNAs hampers replication of morbilliviruses

  • Oliver Siering (Langen / DE)

   Antiviral therapy and resistance, Innate immunity
• • Poster
  • P 040

  Combining latency-reversing agents with type I IFNs accumulates HIV-1 Env on the cell surface and sensitizes for the elimination of HIV-reactivating cells through antibody-dependent cellular cytotoxicity

  • Julia Kazmierski (Berlin / DE)

   Antiviral therapy and resistance, Viral pathogenesis and persistence
• • Poster
  • P 041

  Pyrosequencing analysis for molecular resistance marker PA-I38X of influenza A viruses to baloxavir marboxil

  • Dr. Susanne Duwe (Berlin / DE)

   Antiviral therapy and resistance
• • Poster
  • P 042

  Antiviral activity of small molecules targeting the nsp10/nsp14 complex of coronaviruses

  • Natalie M. Köhler (Hannover / DE)

   Antiviral therapy and resistance, SARS-CoV-2
• • Poster
  • P 043

  Druggability assessment of the bunyaviral cap-binding domain

  • Janna Scherf (Hamburg / DE)

   Antiviral therapy and resistance, Viral replication strategies 1 (RNA viruses)
• • Poster
  • P 044

  Systematic comparison of latency reversing agents on transcription of human T-cell leukemia virus type 1

  • Louisa Rasp (Erlangen / DE)

   Antiviral therapy and resistance, Viral pathogenesis and persistence
• • Poster
  • P 045

  Chimeric antigen receptors as a novel treatment option for cytomegalovirus infections

  • Christopher Bednar (Erlangen / DE)

   Antiviral therapy and resistance
• • Poster
  • P 046

  In vitro screening of a compound library targeting the sphingolipid metabolism reveals potential inhibitors of coronaviral replication

  • Florian Salisch (Giessen / DE)

   Antiviral therapy and resistance, SARS-CoV-2
• • Poster
  • P 047

  HIV-1 N VPR mediates resistance to integrase inhibitors

  • Shenglin Zhu (Duesseldorf / DE)

   Antiviral therapy and resistance
• • Poster
  • P 048

  In vitro efficacy testing of broad-spectrum antivirals Remdesivir, Molnupiravir and Favipiravir in combination with p38 MAPK inhibition against the human pathogenic Puumala orthohantavirus

  • Dr. Daniel Bourquain (Berlin / DE)

   Antiviral therapy and resistance, Emerging viruses and zoonosis
• • Poster
  • P 049

  A comprehensive study of wt and Omicron M^pro mutations

  • Francesco Costacurta (Innsbruck / AT)

   Antiviral therapy and resistance, SARS-CoV-2
• • Poster
  • P 050

  Advanced molecular tweezers with lipid anchors against SARS‑CoV-2 and other respiratory pathogen

  • Tatjana Weil (Ulm / DE)

   Antiviral therapy and resistance, Emerging viruses and zoonosis
• • Poster
  • P 051

  Morus alba root bark extracts – multipotent herbal anti-infectives?

  • Prof. Dr. Michaela Schmidtke (Jena / DE)

   Antiviral therapy and resistance
• • Poster
  • P 052

  Identification and evaluation of a novel tribenzamide derivative as an inhibitor targeting the entry of the respiratory syncytial virus

  • PD Dr. Thomas Grunwald (Leipzig / DE)

   Antiviral therapy and resistance
• • Poster
  • P 053

  Replication of primary HIV-1 strains in macrophages and virus transmission to T cells

  • Sabina Victoria Montero (Tuebingen / DE)

   Antiviral therapy and resistance, Viral pathogenesis and persistence
• • Poster
  • P 054

  Identification of small molecule inhibitors against adenoviral infection

  • Dr. Wing Hang Ip (Hamburg / DE)

   Antiviral therapy and resistance, Viral pathogenesis and persistence
• • Poster
  • P 055

  Identifying novel antivirals and their targets in coronavirus-infected cells

  • Talia Schneider (Hannover / DE)

   Antiviral therapy and resistance, SARS-CoV-2
• • Poster
  • P 056

  Drug resistance associated mutations in splicing regulatory elements affecting HIV-1 gene expression and replication capacity

  • Lisa Müller (Duesseldorf / DE)

   Antiviral therapy and resistance, Viral pathogenesis and persistence
• • Poster
  • P 059

  Assay development for high-throughput antiviral compound screening against bunyavirus L protein

  • Dr. Dominik Vogel (Hamburg / DE)
  • Janna Scherf (Hamburg / DE)
  • Dr. Maria Rosenthal (Hamburg / DE)

   Antiviral therapy and resistance, Viral replication strategies 1 (RNA viruses)
• • Poster
  • P 060

  Ligand-based discovery of coronavirus main protease inhibitors using MACAW molecular embeddings

  • Dr. Mihayl Varbanov (Vandoeuvre les Nancy / FR)

   Antiviral therapy and resistance, SARS-CoV-2
• • Poster
  • P 061

  Enhancing antiviral immunity by blocking SAMHD1 activity and targeting viral immune evasion

  • Aleksandra Mitric (Erlangen / DE)

   Antiviral therapy and resistance, Innate immunity